NIKKEI 225
26,713.38 +310.54 (+1.18%) HANG SENG
20,489.63 +368.95 (+1.83%) CRUDE OIL
110.85 -1.36 (-1.21%) GOLD FUTURES
1,840.90 -0.30 (-0.02%) DOW
31,253.13 -236.94 (-0.75%) BTC-GBP
24,147.40 +673.45 (+2.87%)
NVO Jan 2023 80.000 put
| Previous close | 3.3000 |
| Open | 3.3000 |
| Bid | 2.8000 |
| Ask | 3.9000 |
| Strike | 80.00 |
| Expiry date | 2023-01-20 |
| Day's range | 3.3000 - 3.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Zacks
4 Large Drug Stocks to Watch as the Industry Recovers
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.
- Globe Newswire
Novo Nordisk A/S: Share repurchase programme
Bagsværd, Denmark, 16 May 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiate
- Zacks
Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod
Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.
